AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts. firmnews.title

29 April 2022

9958

2 min.

AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

AstraZeneca today announced plans to open a new site at the heart of the Cambridge, MA, life sciences and innovation hub.

The new site will be a strategic R&D centre for AstraZeneca, as well as Alexion’s new corporate headquarters. The site will bring together approximately 1,500 R&D, commercial and corporate colleagues into a single purpose-built space in Kendall Square, Cambridge, MA.

The site, scheduled for completion in 2026, will be in close proximity to several major academic, pharma and biotech institutions, inspiring greater collaboration and innovation potential, and providing access to future talent. The move reinforces AstraZeneca’s commitment to the greater Boston area, with over 570,000 square feet of R&D and commercial space, and room for expansion for the future.

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “Today’s announcement is a milestone moment following the acquisition of Alexion in July 2021. Our combined company has already successfully leveraged internal scientific synergies, and this move will act as a catalyst for even more external collaboration and innovation.

“Kendall Square, Cambridge, is at the heart of the life sciences and innovation hub of the greater Boston area, and our new site will put us right at the centre of this space. The move will provide access to some of the most innovative partners in academia and biotech, offering opportunities to accelerate our growth and collaborate with like-minded organisations as we continue to push the boundaries of science to deliver advances for patients.”

Notes

AstraZeneca is working with BXP (NYSE:BXP) on development of the new site.

In line with AstraZeneca’s commitment to leading in sustainability, the aim is for the new site to have platinum Leadership in Energy & Environmental Design (LEED) certification, the highest level of certification.

Alexion’s R&D center of excellence will remain in New Haven, Connecticut. Alexion recently signed a lease to expand that campus as well, which will double Alexion’s lab floor space in New Haven by the end of 2023.

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Adrian Kemp
Company Secretary
AstraZeneca PLC

Persons¹ and Companies¹ in the news

SORIOT Pascal

Chief Executive Officer of AstraZeneca

1 place

AstraZeneca

1 place

Tags:

Section:

PRESS RELEASES OF ENGLAND

Press releases GlobalEng.biz -this is the latest news from England companies.

The official press releases of companies in England are regularly published on the resource. You can find out the latest news of enterprises in the corresponding section on the main page. Posting press releases is a traditional and effective way to promote your business. It allows organizations to declare themselves and their products and services to the widest possible mass of the audience. At the same time, the information occasion can be any: attracting people to an event or conference, highlighting new products or personnel appointments. If your goal is to draw attention to your information, then GlobalEng.biz will become your reliable assistant in this case. Thanks to the portal, your press release will be seen by reviewers of leading online publications, customers and partners.

GlobalEng.biz allows representatives of companies and organizations in A to independently post a press release when registering on the resource. The most important feature of GlobalEng.biz.The problem is that all publications of England companies fall into the archives and will be available from the search for a long time. You just need to add a press release to the information feed.

GlobalEng.biz offers its customers a subscription service that allows companies to regularly publish press releases on favorable terms. In addition, the business portal provides an opportunity to tell more fully about the life of the company by adding photos and videos, persons and quotes of employees. All information materials have active links and will lead potential customers to your resource.

Alena Potapova

Development Director